INTRODUCTION {#sec1-1}
============

Neoadjuvant chemotherapy (NAC) treatment for women diagnosed with local-regional disease has been shown to reduce the tumor size of most breast tumors and decrease the incidence of positive nodes.\[[@ref1]\] The 5- and 9-year follow-up results from the National Surgical Adjuvant Breast and Bowel Project B-18 indicate overall survival and disease-free survival were not statistically different between NAC and postoperative adjuvant therapy.\[[@ref2][@ref3]\] NAC has been shown to increase breast-conserving lumpectomy rates.\[[@ref1][@ref2][@ref3]\] Overall survival, disease-free survival, and relapse-free survival are statistically correlated with the pathologic primary tumor response.\[[@ref3]\] Physical examination, ultrasound, and mammography are of limited value for predicting pathologic residual tumor size after NAC.\[[@ref4]\] The use of fluorodeoxyglucose positron emission tomography (FDG-PET) to provide a functional measure of NAC response has been reported.\[[@ref5][@ref6]\] Breast magnetic resonance imaging (MRI) is increasingly considered as the preferred imaging modality for predicting pathologic response.\[[@ref7][@ref8][@ref9]\] The Translational Breast Cancer Research Consortium trial 017 observed that the tumor size from MRI had an overall accuracy of 74% in predicting complete pathologic response and it varied substantially among tumor subtypes.\[[@ref7]\] Another study using MRI observed that changes in tumor volume provided a more sensitive assessment than changes in tumor size.\[[@ref8]\] The American College of Radiology Imaging Network 6657 trial noted that tumor volume changes assessed using MRI early in the NAC cycle had an accuracy of 0.7 for predicting pathologic response.\[[@ref9]\] The study reported that the in-plane spatial resolution for contrast-enhanced MRI was 1 mm or less and that the slice thickness was 2.5 mm or less.\[[@ref9]\] Prior studies with dedicated breast computed tomography (bCT) have shown the ability to provide isotropic voxel dimensions of 0.273 mm or less.\[[@ref10][@ref11][@ref12]\] Even without contrast enhancement, desmoplastic reaction and density changes can be discerned with bCT and clinical studies have shown an improvement in visualizing soft-tissue abnormalities with bCT compared to mammography.\[[@ref12][@ref13][@ref14]\] To our knowledge, there have been no prior reports investigating the use of dedicated bCT for monitoring NAC response. Hence, this prospective pilot study was conducted to determine the feasibility of non-contrast dedicated bCT as an imaging tool to determine primary tumor volume and monitor its changes during NAC.

MATERIALS AND METHODS {#sec1-2}
=====================

Human subjects {#sec2-1}
--------------

This prospective study was conducted in adherence to a Health Insurance Portability and Accountability Act-compliant, institutional review board-approved protocol. Any woman who was recommended for NAC was eligible to participate in the study. All study participants provided written informed consent. Twelve women consented to participate in this pilot feasibility study, which is closed for accrual, of which one participant elected to undergo mastectomy in lieu of NAC and was excluded. Prior to initiation of NAC, 10 of the 11 study participants had a breast MRI exam (one subject had a FDG-PET exam) for extent-of-disease evaluation as part of standard-of-care. The tumor size from breast MRI, breast density from mammography assessed as per the American College of Radiology BI-RADS^®^ criteria, receptor status, diagnosis from histopathology, and the drug combination used for NAC are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Summary of study participants' data

![](JCIS-4-64-g002)

Imaging protocol {#sec2-2}
----------------

All study participants were imaged using a clinical prototype dedicated bCT system (Koning Corporation, West Henrietta, NY, USA). The system uses a tungsten-anode X-ray tube operating at 49 kVp, an amorphous silicon flat-panel detector, and acquires 300 projections covering 360° in 10 s.\[[@ref10][@ref11][@ref12]\] The mean glandular dose (MGD) from a bCT scan is similar to and within the range from diagnostic mammography.\[[@ref11]\] The study participant was positioned prone on the patient support table with slight oblique rotation to facilitate inclusion of the axillary region and the breast was pendant through the aperture in the table. The manufacturer-provided filtered-back projection algorithm was used to reconstruct the breast at isotropic voxel size of 0.273 mm. All studies were performed without administration of contrast media.

The imaging protocol called for each study participant to undergo non-contrast bCT exams of the ipsilateral breast containing the index lesion at three time-points: Pre-treatment- before starting NAC; mid-treatment- after 4 cycles of doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) and before 4 cycles of either paclitaxel (Taxol) or the combination of 12 weekly cycles of paclitaxel (Taxol) and trastuzumab (Herceptin) for those who were Her2-neu positive; and, post-treatment- after completion of NAC. Of the 11 women who were enrolled in the study and underwent NAC, 2 study participants did not appear for their mid-treatment bCT exam. Where analysis permitted, bCT volumes from these two study participants were included.

Radiologist\'s segmentation {#sec2-3}
---------------------------

The reconstructed breast volumes were displayed on a 3-D workstation (Visage 7; Visage Imaging Inc., San Diego, CA, USA) provided with the bCT system. The workstation facilitates viewing of the breast volume in any desired orientation and includes tools for image manipulation and quantitative analysis. A single radiologist (study author) marked the tumor boundary in multiple coronal views, from which the workstation computed the tumor volume \[[Figure 1](#F1){ref-type="fig"}\]. The tumor volume from radiologist\'s manual segmentation served as the reference for comparison with the estimate from automated segmentation.

![48-year-old woman diagnosed with invasive ductal carcinoma. Radiologist segmented the tumor from multiple coronal images. Volume-rendered (3-D) breast CT images show the tumor volume obtained at (a) pre-treatment, (b) mid-treatment, and (c) post-treatment.](JCIS-4-64-g003){#F1}

Automated segmentation {#sec2-4}
----------------------

An automated segmentation algorithm (MatLab^®^ version 8.1, The MathWorks Inc., Natick, MA, USA) was developed \[[Figure 2](#F2){ref-type="fig"}\] by partly utilizing techniques for segmenting breast tissue in tomographic images.\[[@ref10][@ref15]\] The skin layer was removed so as to minimize the possibility of skin being classified as tumor, when the tumor is at breast periphery.\[[@ref16]\] For the pre-treatment bCT exam, the algorithm leveraged the tumor location indicated by the biopsy clip. After excluding the coronal slices that contained the biopsy clip to mitigate beam-hardening artifacts, the breast volume was divided into regions posterior and anterior to the clip. Since the biopsy clip was 3 mm in size, a total of 11 slices, each 0.273 mm thick, were excluded. A bilateral filter was applied to each region for edge-preserving noise reduction prior to segmentation.\[[@ref17]\] Each region was segmented using two iterations of Kernel-based fuzzy c-means algorithm.\[[@ref18]\] The first iteration classified the breast volume into adipose and non-adipose tissues, and the second iteration used the non-adipose tissue volume to classify it into fibroglandular and cancerous tissues. The biopsy clip location was translated to the boundary of the posterior and anterior regions and served as a location-seed for a volume-growing algorithm applied to the cancerous tissue. The tumor volume was determined after interpolating for the slices that were excluded due to the clip. The mid-treatment and post-treatment bCT exams were registered with the pre-treatment bCT exam using 3D slicer,\[[@ref19]\] as the biopsy clip may migrate over time. The tumor from mid-treatment and post-treatment bCT exams was segmented in a similar manner as the pre-treatment bCT exam. Once the tumor was segmented, an automated algorithm was used to determine the largest extent of tumor (size) in the sagittal plane that corresponds to the manner in which the specimen is sectioned by pathology to determine concordancy with pathology. An example of the segmented tumor is shown in [Figure 3](#F3){ref-type="fig"}.

![The automated algorithm with two iterations of kernel-based fuzzy c-means (KFCM) segmentation.](JCIS-4-64-g004){#F2}

![41-year-old woman diagnosed with invasive ductal carcinoma at 6-o'clock position. (a--d) Cross-sectional (coronal) slices from post-treatment bCT exam performed prior to surgery show the contour (red) of the tumor segmented using the developed algorithm. The slices progress from the nipple toward the chest wall. The largest tumor dimension (size) was estimated over all sagittal planes that correspond to the manner in which the surgical specimen is sectioned by pathology. Tumor size determined using the algorithm was 2.82 cm. Pathology reported tumor size of 3 cm.](JCIS-4-64-g005){#F3}

Statistical analysis {#sec2-5}
--------------------

Parametric or non-parametric tests (SAS 9.3; SAS Institute Inc., Cary, NC, USA), depending on the results from normality test (Shapiro--Wilk test), were used to analyze the correlation in tumor volumes between the modalities (MRI and bCT) and between the segmentation methods (automated and manual). If the data did not satisfy the normality assumption, then logarithmic transform was attempted. The agreement was characterized by Bland--Altman plots. The influence of breast density on the estimated tumor volume was also investigated. The correlation between the tumor sizes obtained from post-treatment bCT and from pathology was determined. Effects associated with *P* \< 0.05 were considered statistically significant.

RESULTS {#sec1-3}
=======

Comparison of automated and manual segmentation of bCT images {#sec2-6}
-------------------------------------------------------------

The distribution of the difference in tumor volumes between manual and automated segmentations after grouping over all three time points (pre-, mid-, and post-treatment) did not satisfy the normality assumption (Shapiro--Wilk test, *P* = 0.043) and needed logarithmic transformation. Subsequent analyses reported in this section use log-transformed tumor volumes. Tumor volumes from automated and manual segmentations (*n* = 31 bCT scans) were correlated (Pearson\'s *r* = 0.935, *P* \< 0.001). Result from the linear regression analysis is shown in [Figure 4a](#F4){ref-type="fig"}, along with the identity line (dashes). The analysis showed high coefficient of determination (*r*^2^ = 0.875), and the fit-parameters indicated a non-zero intercept and a slope less than unity. Hence, a Bland--Altman plot \[[Figure 4b](#F4){ref-type="fig"}\] was generated which showed good agreement with most of the data points located within the limits of agreement (±1.96 standard deviation) and a mean difference close to zero. The possibility that breast density could influence the automated segmentation was investigated. The percent difference in tumor volume was computed as, \[(*V~MbCT~* − *V~AbCT~*)/*V~MbCT~*\] × 100%, where *V~MbCT~* and *V~AbCT~* are the log-transformed tumor volumes from manual and automated segmentations, respectively. This metric was not statistically different among the breast density categories (Kruskal--Wallis test, *P* = 0.169). Repeated measures analysis of variance (ANOVA) indicated that the segmentation methods (automated or manual) did not have a statistically significant effect on the tumor volumes (*P* = 0.808) and that the changes in tumor volume over time were not dependent on the segmentation method (Wilk\'s lambda, *P* = 0.316). As expected, changes in tumor volume over the course of NAC were statistically significant (*P* \< 0.001).

![(a) Linear regression analysis of tumor volumes from automated and radiologist\'s manual segmentation. (b) Bland--Altman plot showing the agreement in tumor volumes between automated and manual segmentation. The tumor volumes are after logarithmic transformation.](JCIS-4-64-g006){#F4}

Correlation with pre-treatment breast MRI {#sec2-7}
-----------------------------------------

The tumor size from the pre-treatment breast MRI (*n* = 10 subjects) interpretation report \[[Table 1](#T1){ref-type="table"}\] was used to estimate the tumor volume based either on ellipsoidal approximation for tumor shape when two or more dimensions were reported or on spherical approximation when only one dimension was reported. The pre-treatment tumor volume from MRI was compared with the pre-treatment tumor volume from bCT that was obtained by averaging the estimates from automated and manual segmentations. After logarithmic transformation, the tumor volumes satisfied the normality assumption (Shapiro--Wilk test, *P* \> 0.316). Log-transformed tumor volumes from MRI and bCT were statistically correlated (Pearson\'s *r* = 0.905, *P* \< 0.001). Linear regression analysis \[[Figure 5a](#F5){ref-type="fig"}\] showed high coefficient of determination (*r*^2^ = 0.819), slope approaching unity (0.933), and a non-zero intercept (−0.124). The Bland--Altman plot \[[Figure 5b](#F5){ref-type="fig"}\] showed good agreement with all the data points located within the limits of agreement (±1.96 standard deviation). However, the mean difference was substantially different from zero. Hence, the influence of mammographic breast density was investigated. The percent difference in tumor volumes between MRI and bCT was calculated in a manner similar to above and did not exhibit a statistical difference among the breast density categories (Kruskal--Wallis test, *P* = 0.312).

![(a) Linear regression analysis of pre-treatment tumor volumes from MRI and bCT. The tumor volumes from bCT are represented by the mean and ± 1 standard deviation of the estimates from automated and radiologist\'s segmentations. (b) Bland--Altman plot showing the agreement in tumor volumes between MRI and bCT. The tumor volumes are after logarithmic transformation.](JCIS-4-64-g007){#F5}

Correlation with histopathology {#sec2-8}
-------------------------------

Histopathology results indicated that three subjects had no residual invasive tumor, one subject had invasive ductal carcinoma (IDC) with microscopic foci of 0.8 and 1 mm, and one subject had a 4 mm residual IDC. The presence of biopsy clip (3 mm) in all subjects and associated beam-hardening artifacts in bCT limited the ability to measure tumors of size approaching that of the biopsy clip. Hence, tumors smaller than 5 mm, which correspond to the upper bound for pT1, a primary tumor classification,\[[@ref20]\] were excluded from the analysis. Also, pathology report indicated that one subject had scattered foci of residual invasive lobular carcinoma (ILC) in three quadrants spanning approximately 16 cm, of which the largest focus was 8 mm. The tumor size determined from bCT for this subject was 9.5 cm. Limiting the analysis to IDC of size larger than 5 mm (*n* = 5 subjects), tumor size from post-treatment bCT was statistically correlated with pathology (Pearson\'s *r* = 0.987, *P* = 0.002). Also, the post-treatment tumor volume (log-transformed) from bCT was statistically correlated with tumor size from pathology (Pearson\'s *r* = 0.908, *P* = 0.033) for this sub-group. Prior studies investigating concordance in tumor size between pathology and imaging modalities have used thresholds of 0.5, 1, and 2 cm.\[[@ref21][@ref22][@ref23]\] Applying the median threshold from these studies (1 cm), all subjects in this sub-group (ILC and pT1a or smaller excluded) were concordant \[[Figure 6](#F6){ref-type="fig"}\] and the maximum difference in tumor size between pathology and post-treatment bCT was 0.57 cm for a subject assigned pT1b with 0.8 cm IDC.

![The absolute difference in tumor size between post-treatment bCT and pathology is plotted as a function of tumor size from pathology. For invasive ductal carcinoma (IDC) and for tumors larger than 0.5 cm (upper bound of pT1a primary tumor classification), tumor size from bCT was concordant with pathology at 1 cm threshold.](JCIS-4-64-g008){#F6}

Temporal changes in tumor size and volume {#sec2-9}
-----------------------------------------

Temporal changes in tumor volume (log-transformed) determined using bCT from pre-treatment to mid-treatment and from mid-treatment to post-treatment are shown in Figure [7a](#F7){ref-type="fig"} and [b](#F7){ref-type="fig"}, respectively. The tumor volumes from bCT at each time point were obtained by averaging the estimates from automated and manual segmentations. The identity line is included for visual analysis. Reduction in tumor volume was observed at mid-treatment \[[Figure 7a](#F7){ref-type="fig"}\] and was statistically different from pre-treatment tumor volume (paired *t*-test, *P* = 0.0003). The intercept from the linear regression analysis indicates that the tumor volume reduction averaged across all nine subjects who appeared for mid-treatment bCT was 47% (1--10 ^−0.273^). Adapting the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) which is intended for tumor size, all study participants who appeared for the mid-treatment bCT exam experienced at least a 30% reduction in tumor volume from pre-treatment.\[[@ref24]\] A further reduction in tumor volume from mid-treatment to post-treatment (paired *t*-test, *P* = 0.002) is observed in [Figure 7b](#F7){ref-type="fig"} and the reduction averaged over all subjects was 34%. Comparison of the largest tumor dimension from pre-treatment MRI with the tumor size from pathology showed a reduction in tumor size for all subjects, indicating qualitative agreement with the temporal volume changes observed with bCT. Pathology confirmed partial (*n* = 8 subjects) or complete (*n* = 3 subjects) response for invasive tumor. The proportion of subjects with pathologic complete response was 27.3% (3/11) for subjects treated with doxorubicin (Adriamycin), cyclophosphamide (Cytoxan), paclitaxel (Taxol) (ACT) drug combination \[[Table 1](#T1){ref-type="table"}\] and is similar to the 26% reported in NSABP-B27 trial.\[[@ref25]\]

![Temporal changes in tumor volume determined using bCT (a) from pre-treatment to mid-treatment and (b) from mid-treatment to post-treatment. Tumor volumes are after logarithmic transformation. All study participants experienced either partial or complete pathologic response. Reduction in tumor volume could be observed at mid-treatment with bCT.](JCIS-4-64-g009){#F7}

DISCUSSION {#sec1-4}
==========

Prior studies have used fuzzy c-means based approach for segmenting bCT images to skin, adipose, and fibroglandular tissue.\[[@ref10][@ref26]\] It has been shown to be accurate to within ± 1.9% in estimating the volume of an irregular shaped object.\[[@ref10]\] However, the presence of biopsy clip in all subjects limits the ability of the algorithm to determine tumor volume approaching the size of the clip. This results in slope less than unity in the linear regression analysis \[[Figure 4a](#F4){ref-type="fig"}\]. Excluding the three smallest tumors and repeating the linear regression analysis improved the slope to 0.873 and intercept to 0.077. Referring to [Figure 4a](#F4){ref-type="fig"}, the tumor volume from automated segmentation was higher than the manual (radiologist\'s) segmentation for the three smallest tumors, suggesting that the beam-hardening artifacts from the biopsy clip had less influence on radiologist\'s segmentation. The beam-hardening artifacts from the biopsy clip can be suppressed by metal-artifact reduction algorithms.\[[@ref27]\] This could potentially improve the accuracy for estimating the volume of smaller tumors and will be investigated in future.

In the absence of multifocal or multicentric disease, ultrasound is often used for extent-of-disease evaluation. However, ultrasound has lower sensitivity than MRI and underestimates the tumor size compared to MRI.\[[@ref22][@ref28]\] A recent study of 149 cancers reported that the concordance and correlation with pathology was highest for MRI and was better than mammography, ultrasound, or digital breast tomosynthesis.\[[@ref29]\] Hence, the choice of MRI as reference standard for comparison with bCT for extent-of-disease evaluation is appropriate. Comparison of tumor volumes from pre-treatment breast MRI and bCT indicated a negative intercept in the linear regression analysis \[[Figure 4a](#F4){ref-type="fig"}\] and a mean difference of 0.23 in the Bland--Altman plot \[[Figure 4b](#F4){ref-type="fig"}\]. This implies that the tumor volume from bCT was smaller compared to MRI. Overestimation of tumor size by MRI compared to pathology has been reported.\[[@ref22][@ref23]\] It has also been noted that the contrast (Gd) enhancement of the *in situ* component associated with the invasive tumor could be the source of overestimation with breast MRI.\[[@ref22]\] Also, the tumor volume from MRI was based on ellipsoidal or spherical approximation of tumor size from interpretation reports, as 3/10 subjects underwent breast MRI at institutions not associated with the study. Future studies will implement an MRI segmentation algorithm.

A search of the PubMed database did not identify any prior reports investigating the use of *dedicated bCT* for monitoring NAC response or for evaluating tumor size. However, there have been several studies using contrast-enhanced conventional (chest) CT to assess NAC response for breast cancer and to determine the tumor size.\[[@ref30][@ref31][@ref32][@ref33][@ref34][@ref35]\] In a study of 285 patients with unifocal invasive breast carcinoma, 80% concordance with pathology at 5 mm threshold was observed with contrast-enhanced chest CT.\[[@ref35]\] One study comparing contrast-enhanced and non-contrast chest CT for visualization of known breast tumors concluded that contrast enhancement is not needed to visualize known tumors in most patients.\[[@ref36]\] One major advantage with dedicated bCT compared to conventional CT is that the radiation dose is limited primarily to the breast with the rest of the body receiving minimal dose.\[[@ref37]\] This is of particular importance if contrast enhancement and the determination of perfusion parameters were to be pursued, which seem to be of value in predicting the response to NAC with conventional chest CT.\[[@ref34]\]

It is also important to consider the radiation dose from bCT in the context of subsequent treatment. Post NAC, patients undergo either mastectomy or breast conserving surgery followed by whole breast radiation therapy depending on the effectiveness of NAC and other factors.\[[@ref38]\] For patients who undergo mastectomy, the radiation-associated risk from bCT is negligible. For patients who undergo breast conserving surgery, radiation therapy delivers 40--50 Gy.\[[@ref39]\] This is 2 orders of magnitude higher or more than the cumulative dose from the three bCT scans. It is also relevant to note that the consensus statement on the use of accelerated partial breast irradiation (APBI) recommended that patients who underwent NAC should not receive APBI outside of a clinical trial due to lack of sufficient data.\[[@ref40]\] Thus, the radiation-associated risk from dedicated bCT for monitoring NAC response is minimal.

Limitations {#sec2-10}
-----------

The primary limitation of this study was the small sample size. This pilot study with a small number of study participants was intended to demonstrate the feasibility of non-contrast bCT to measure tumor volume (size) and monitor its changes during NAC. The results from this feasibility study show promise and indicate that a larger study is warranted. Additional limitations of the study were that the tumor volume was determined by a single radiologist and that the tumor volume from MRI was based solely on the radiologist\'s report and not from segmentation. A larger study is planned that would include concurrent breast MRI and dedicated bCT at each time point and measurements of tumor volume (size) by multiple radiologists to determine inter-observer variability.

CONCLUSION {#sec1-5}
==========

In summary, this prospective study investigated the feasibility of non-contrast bCT as an imaging tool to determine primary tumor volume and monitor its changes during NAC. An automated segmentation algorithm was developed and tumor volumes from the automated segmentation were correlated with radiologist\'s segmentation. Considering the study did not use contrast enhancement, the observations of reduction in tumor volume at mid-treatment in pathology-assessed responders, and statistical correlation and concordance in tumor size between bCT and pathology at post-treatment for tumors (IDC) larger than 5 mm are suggestive of potential benefits. This suggests that contrast enhancement may not be necessary for all subjects and needs further validation. Also, the observation that a larger reduction in tumor volume occurred between pre-treatment and mid-treatment than between mid-treatment and post-treatment suggests that bCT may be of value in predicting NAC response by mid-treatment. A larger study is needed to determine if tumor volume changes observed with bCT are predictive of pathologic response. The data also indicate that correction for beam-hardening effects from biopsy clip (if present) is needed to evaluate the size of smaller tumors. While this study investigated the feasibility of bCT for monitoring NAC response, some of the observations may also be applicable for evaluating tumor size for diagnostic imaging and surgical planning. The encouraging results from this feasibility study indicate that it would be of value to pursue larger studies.
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